Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (December 2017)
38 slides from Noxopharm's investor presentation, Dec 6, 2017
Slide 1: NOX Open Briefing Corporate Presentation
Date: 6 December 2017 Sydney, Australia For personal use only ASX: NOX ASX Limited 20 Bridge Street Noxopharm Limited SYDNEY NSW 2000 ABN 50 608 966 123 Registered Office: NOX OPEN BRIEFING CORPORATE PRESENTATION Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia Sydney, 6 December 2017: Noxop
Slide 2: Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “wo
Slide 3: Open Briefing 6 December 2017
For personal use only Open Briefing 6 December 2017 1
Slide 4: Oncology
For personal use only 2 ONCOLOGY
Slide 5: Noxopharm NOX66 Idronoxil (lipophilic form)
Noxopharm For personal use only NOX66 Idronoxil (lipophilic form) 3
Slide 6: About Idronoxil
Noxopharm ABOUT IDRONOXIL For personal use only Multiple anti-cancer actions 1. Inhibits DNA repair (inhibits PARP-1, topoisomerases 1 and 2) 2. Promotes anti-tumour immunity (Increases NK (natural killer) cell activity) 4
Slide 7: Oral Idronoxil NOX66 LIPROSE Technology
Noxopharm Oral Idronoxil NOX66 For personal use only LIPROSE Technology Excreted Excreted quickly slowly (45 min) (10 hours) Does NOT Crosses BBB cross BBB 5
Slide 8: DARRT: Direct and Abscopal Response to Radio-Therapy
Noxopharm For personal use only DARRT Direct and Abscopal Response to Radio-Therapy 6
Slide 9: Limitation of radiotherapy
Limitation of radiotherapy Noxopharm Metastatic cancer too extensive for radiation For personal use only 7
Slide 10: Direct Response to Radio-Therapy
DIRECT Response to Radio-Therapy Noxopharm For personal use only Radiotherapy applied to large Shrinkage of irradiated Direct radio-sensitising effect tumours tumours for pain relief 8
Slide 11: Direct Response to Radio-Therapy with NOX66
DIRECT Response to Radio-Therapy Noxopharm For personal use only NOX66 Radiotherapy applied to large Shrinkage of irradiated Seeking complete remission of Direct radio-sensitising effect Direct radio-sensitising irradiated tumours effect tumours for pain relief tumours 9
Slide 12: Abscopal Response to Radio-Therapy
ABSCOPAL Response to Radio-Therapy Noxopharm For personal use only Exposed tumours respond ✙ Non-exposed tumours also respond Low-dose radiotherapy Seeking Direct complete remission radio-sensitising effectof Abscopal response irradiated tumours 10
Slide 13: Features of an abscopal response
Noxopharm Features of an abscopal response For personal use only Rare – very rare phenomenon Complete – primary AND secondary tumours respond Durable – potentially permanent Unrestricted – range of cancers reportedly involved Short treatment – single course of treatment (7-14 days) Low toxicity – lo
Slide 14: DARRT: external beam RT trial design
DARRT Noxopharm For personal use only Direct Effect Abscopal Effect Ø Patients with multiple (>3) tumours Ø Irradiate 1-2 tumours (5 days) External Beam RT Ø NOX66 14 days Ø Scan + 2 months and 4 months 12
Slide 15: DARRT: target cancers
DARRT Noxopharm For personal use only Direct Effect Abscopal Effect Ø Prostate cancer (metastatic castrate-resistant) Ø Solid common cancers (eg. lung, breast, melanoma) External Beam RT Ø Rare cancers (eg. sarcomas) 13
Slide 16: DARRT: brachytherapy with Lutetium-PSMA-617
DARRT Noxopharm For personal use only Direct Effect Abscopal Effect Ø 177 Lutetium-PSMA-617 Ø 4 x monthly intravenous injections of LuPSMA/10 Brachytherapy days NOX66 Ø Prostate cancer (metastatic castrate-resistant) 14
Slide 17: NOX66-001 Phase 1b Study Georgia
DARRT Noxopharm For personal use only Where NOX66 + Radiotherapy needs a boost ……… NOX66-001 Phase 1b Study Georgia + Low-dose carboplatin (AUC4 – monthly) 400 mg NOX66 5 patients: 1 progressive; 4 non-progressive 800 mg NOX66 7 patients: 1 progressive; 5 non-progressive; 1 partial response 15
Slide 18: What will a 'good response' look like?
Noxopharm What will a ‘good response’ look like ? For personal use only • Lung Cancer trial (582 patients evaluated) • Opdivo vs standard chemotherapy • Survival of 50% of patients - 12.2 months v 9.4 months • Time to disease progression – 2.3 months v 4.2 months • Overall Response Rate – 19% v 12%
Slide 19: Moving towards first registration
Noxopharm For personal use only Moving towards first registration Notes: Target Indication: NOX66 in combination with Radiotherapy for the • Different Global Regulators treatment of patients with metastatic cancer may modify indication for specific tumour types Studies: • Indication may also list NO
Slide 20: Beyond the trials to reach registration
Noxopharm For personal use only Beyond the trials to reach registration • Manufacturing and formulation: Optimise NOX66 formulation; GMP Manufacturing • Pre-clinical / non-clinical: in vitro and animal studies to meet regulatory and other requirements for registration and marketing NEW!! • Medical A
Slide 21: Communicating Trials Progress 2018
Noxopharm Communicating Trials Progress 2018 For personal use only • Progress – based on Data Safety Monitoring Committee Review • Independent body – researchers and statisticians • Regular meetings during trials – expect ~6 across trials in 2018 • Review overall progress à decisions on continuation
Slide 22: For personal use only
For personal use only 20
Slide 23: Nyrada technologies, drugs and indications
For personal use only 2 technologies 3 drugs 3 indications NYX-104 v Stroke v Concussion LIPROSE v Severe epilepsy NYX-205 Peripheral neuropathy Nyx-104 P-PDT NYX-330 Hypercholesterolaemia 21
Slide 24: NYX-104 Inhibitor of excitotoxicity
NYX-104 Inhibitor of excitotoxicity For personal use only head stroke trauma Excitotoxicity epilepsy concussion 22
Slide 25: NYX-104
NYX-104 For personal use only Receptors activated by small amount of Small amount of glutamate. Ca++ allowed to enter neuron, activating a series of events that leads to generation of an electrical signal. 23
Slide 26: NYX-104 Excitotoxicity
NYX-104 For personal use only Excitotoxicity Size of original area of Days to weeks later, damage from stroke excitotoxicity has increased area or concussion of damage up to 10-times 24
Slide 27: NYX-104
NYX-104 For personal use only 1. University of NSW Translational Neuroscience Facility: Breakthrough identification of key protein promoting excitotoxicity (TrpC3 isotope) 2. In vitro screen of NOX compounds: NYX-104 inhibits TrpC3 3. Mouse model of human stroke: NYX-104 is potent inhibitor of excit
Slide 28: NYX-205 Anti-inflammatory
NYX-205 Anti-inflammatory Designed to cross the blood-nerve barrier For personal use only Diabetes Chemotherapy Peripheral neuropathy Alcoholism Shingles 26
Slide 29: NYX-205 Peripheral neuropathy
NYX-205 Peripheral neuropathy For personal use only Incidence in US estimated at 20 million: Blood-nerve barrier is major obstacle to • Diabetes effective treatment. NYX-205 designed to cross • Alcohol abuse this barrier. • Chemotherapy 27
Slide 30: NYX-205 Peripheral neuropathy
NYX-205 Peripheral neuropathy For personal use only Targeting peripheral neuropathy in cancer patients receiving chemotherapy 60% incidence at 3 months 30% incidence at 6 months Currently no effective treatment 28 NIH
Slide 31: NYX-330 Hypercholesterolemia
NYX-330 Hypercholesterolemia For personal use only Heart Stroke disease High blood LDL Hypertension Alzheimer’s 29
Slide 32: NYX-330 Hypercholesterolemia
NYX-330 Hypercholesterolemia For personal use only • PCSK9 identified as superior drug target compared to statin drugs for lowering blood LDL levels. • PCSK9 is plasma protein that binds to the LDL-LDL receptor complex, preventing recycling of the LDL receptor and thereby increasing LDL levels. PCSK
Slide 33: NYX-330 Hypercholesterolemia
NYX-330 Hypercholesterolemia For personal use only Suitable binding site identified on PCSK9 for attachment of small molecule. NYX-330 blocks binding of PCSK9 to LDL- LDL receptor complex. 31
Slide 34: Nyrada overview
For personal use only Ø US-registered Ø Focus on small molecules, non-oncology Ø 67% owned by NOX; 33% Altnia Holdings Ø Currently public unlisted; proposed US listing in 12-18 months 32
Slide 35: Offer
OFFER: For personal use only Ø Raise = AUD$6,000,000 Ø Seed capital = 1,500,000 New Shares (A$4 each; 2 Options per 3 Shares) Ø Capital structure post-exercise of Options • NOX 50% • Altnia 25% • Seed investors 25% Application for Shares by sophisticated investors, non-US residents only. Information
Slide 36: Disclaimer
For personal use only Disclaimer • This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 37: www.nyrada.com
For personal use only 35 www.nyrada.com
Slide 38: Contact
For personal use only Contact 36